Background:
The impact of low expression of
Glutathione peroxidase 3 (GPX3)
on the clinical course of acute myeloid leukemia (AML) is poorly investigated.
Aims:
To explore the status of
GPX3
expression and analyze its clinical characteristics and prognosis in a cohort of Egyptian patients with AML.
Methods:
GPX3 mRNA level was assessed by RT-q PCR in 40 newly diagnosed AML patients and 10 healthy controls.
Results:
The gene expression level was significantly lower in AML patients than the control group (P < 0.001). A cut off value (0.1223) for the discrimination between AML and controls was obtained by ROC curve. According to this cutoff value; the patients were reassigned into 2 groups; 28 patients with lower
GPX3
expression and 12 patients with high
GPX3
expression.
GPX3
low
expression was significantly associated with higher incidence of induction death (P= 0.037) and lower CR rate (P=0.048). Moreover,
GPX3
low
expression was significantly associated with shorter cumulative 1-year overall survival (OS) (P = 0.001) and disease-free survival (DFS) (P=0.028).
Conclusion:
GPX3
low
expression status is considered a poor prognostic factor in AML predicting shorter OS and DFS. The study highlights the importance of targeting glutathione metabolism as a central component of the anti-leukemia therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.